

Literaturverzeichnis

1. Lundin J, Lehtimäki T, Lundin M, et al: Generalisability of survival estimates for patients with breast cancer: A comparison across two population-based series. *Eur J Cancer* 42:3228-3235, 2006
2. Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for breast cancer. *J Clin Oncol* 14:2197-2205, 1996
3. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and Carboplatin with Autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. *J Clin Oncol* 10:102-110, 1992
4. Ayash LJ, Elias A, Wheeler C, et al: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study. *J Clin Oncol* 12:37-44, 1994
5. Gisselbrecht C, Extra JM, Lotz JP, et al: Cyclophosphamide/mitoxantrone/Melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. *Bone Marrow Transplant* 18:857-863, 1996
6. Abraham R, Nagy T, Goss PE, Crump M: High-dose chemotherapy and Autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases. *Cancer* 88:790-795, 2000
7. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment of metastatic breast cancer: A randomized trial. *J Clin Oncol* 13:2483-2489, 1995
8. Weiss RB, Rifkin RM, Stewart FM, et al: High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study. *Lancet* 355:999-1003, 2000
9. Antman KH, Rowlings PA; Vaughan WP, et al: High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. *J Clin Oncol* 15:1870-1879, 1997
10. Crump M, Gluck S, Tu D, et al: Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. *J Clin Oncol* 26:37-43, 2008
11. Disis ML, Wallace DR, Gooley TA, et al: Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. *J Clin Oncol* 27:4685-4692, 2009
12. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with Trastuzumab in women with ErbB2-positive, Trastuzumab-refractory metastatic breast cancer. *J Clin Oncol* 28:1124-1130, 2010
13. Gianni L, Llado A, Bianchi G, et al: Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
14. Baselga J, Gelmon KA, Verma S, et al: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. *J Clin Oncol* 28:1138-1144
15. Wardley AM; Pivrot X, Morales-Vasquez F, et al: Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. *J Clin Oncol* 28:976-983, 2010
16. Cannistra SA: The ethics of early stopping rules: Who is protecting whom?. *J Clin Oncol* 22:1542-1545, 2004
17. Ozols RF: Maintenance therapy in advanced ovarian cancer: Progression-free survival and clinical benefit. *J Clin Oncol* 21:2451-2453, 2003
18. Aigner KR: Regionale Chemotherapie beim primären und metastasierten Mammakarzinom. *Deutsche Zeitschrift für Onkologie* 41:1-4, 2009
19. Aigner KR: Subclavian artery infusion as induction and adjuvant chemotherapy for breast conserving treatment of primary breast cancer. *Cancer Therapy* 6:67-72, 2008
20. Aigner KR: Hypoxic abdominal perfusion for recurrent platinum refractory ovarian cancer. *Cancer Therapy* 6:213-220, 2008
21. Aigner KR: Isolated thoracic perfusion for chest wall recurrences. Submitted for publication
22. Aigner KR, Knapp N: Quality of life and performance after regional chemotherapy vs. systemic chemotherapy. In Vorbereitung